Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib combined with methotrexate and temozolomide with or without anti-CD20 antibody for relapsed or refractory primary CNS diffuse large B-cell lymphoma
ChiCTR1900025508Phase 4Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibrutinib, methotrexate and temozolomide in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by Fujian Medical University Union Hospital. Primary endpoint: Overall response rate. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
ibrutinibmethotrexatetemozolomide
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR1900025508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025508.